Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
1486.8(c) 1496.8(c) 1485.8(c) 1531.4(c) 1522.8(c) Last
7 066 556 8 652 853 7 507 566 19 634 505 6 492 227 Volume
-0.05% +0.67% -0.73% +3.07% -0.56% Change
More quotes
Financials (GBP)
Sales 2018 30 372 M
EBIT 2018 8 143 M
Net income 2018 3 409 M
Debt 2018 20 469 M
Yield 2018 5,22%
Sales 2019 31 266 M
EBIT 2019 8 413 M
Net income 2019 4 185 M
Debt 2019 19 797 M
Yield 2019 5,24%
P/E ratio 2018 21,96
P/E ratio 2019 17,16
EV / Sales2018 3,17x
EV / Sales2019 3,06x
Capitalization 75 962 M
More Financials
Company
GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
09/24As China builds biotech sector, cash floods U.S. startups
RE
09/22GLAXOSMITHKLINE : The BMJ Questions Transparency of Information Surrounding Safe..
AQ
09/21GLAXOSMITHKLINE : GSK and Tres Cantos Open Lab Foundation announce additional £5..
PU
09/21GLAXOSMITHKLINE : Philly's U.S. attorney pursuing corporate espionage and white ..
AQ
09/21GlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
DJ
09/21GLAXOSMITHKLINE : CHMP recommends expansion of Trelegy COPD label
PU
09/21GLAXOSMITHKLINE : MILITARY $5.09 Million Federal Contract Awarded to GlaxoSmithK..
AQ
09/20GLAXOSMITHKLINE : New HIV/AIDS Findings Reported from GlaxoSmithKline plc (Bioeq..
AQ
09/20GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Prostatic Hyp..
AQ
09/20MANAGEMENT TRACKS : GSK adds Corsico, Enzmann to chair CHMP
AQ
More news
Sector news : Pharmaceuticals - NEC
09/24ASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
09/24ALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
09/24ASTRAZENECA : Mixed Results from Farxiga Trial
DJ
09/24SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/24As China builds biotech sector, cash floods U.S. startups
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
Latest Tweets
09/21Chutes & Ladders—Corsico jumps from Boehringer to head development at Gla.. 
09/21$INVA: Innoviva: Trelegy Ellipta receives positive CHMP opinion supporting ex..
2
09/21$GSK: GlaxoSmithKline and Innoviva (INVA) announce Trelegy Ellipta receives p.. 
09/21Chutes & Ladders—Corsico jumps from Boehringer to head development at Gla..
1
09/21GlaxoSmithKline : GSK and Tres Cantos Open Lab Foundation announce additional.. 
More tweets
Qtime:155
News from SeekingAlpha
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/24Gilead to launch generic versions of Epclusa and Harvoni 
09/21European advisory group backs expanded use for Glaxo's Trelegy Ellipta 
09/20Entasis Therapeutics Readies $75 Million IPO Plan 
09/18Glaxo fielding multiple bids for Indian Horlicks unit 
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 16,5  GBP
Spread / Average Target 7,5%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE15.80%99 260
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092